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The phosphatidylinositol-3-kinase (PI3K)/Akt and the mammalian target of rapamycin
(mTOR) signaling pathways are two pathways crucial to many aspects of cell growth and
survival, in physiological as well as in pathological conditions (e.g., cancer). Indeed, they
are so interconnected that, in a certain sense, they could be regarded as a single, unique
pathway. In this paper, after a general overview of the biological significance and the main
components of these pathways, we address the present status of the development of spe-
cific PI3K, Akt, and mTOR inhibitors, from already registered medicines to novel compounds
that are just leaving the laboratory bench.
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INTRODUCTION
The phosphatidylinositol-3-kinase (PI3K)/Akt and the mam-
malian target of rapamycin (mTOR) signaling pathways are both
crucial to many aspects of cell growth and survival, in physiological
as well as in pathological conditions. They are so interconnected
that, in a certain sense, they could be regarded as a single, unique
pathway (Figure 1) that, in turn, heavily interacts also with many
other pathways, including that of the hypoxia inducible factors
(HIFs).
The PI3K/Akt pathway is a key regulator of survival during
cellular stress (1). Since tumors exist in an intrinsically stressful
environment (characterized by limited nutrient and oxygen sup-
ply, as well as by low pH), the role of this pathway in cancer appears
to be crucial.
Mammalian target of rapamycin is a serine/threonine kinase
ubiquitously expressed in mammalian cells (2). It picks up and
integrates signals initiated by nutrient intake, growth factors, and
other cellular stimuli to regulate downstream signaling and protein
synthesis. Through its downstream effectors, 4EBP1 and P70S6
kinase (S6K), it is involved in the initiation of ribosomal transla-
tion of mRNA into proteins necessary for cell growth, cell cycle
progression, and cell metabolism.
Somatic mutations and/or gains and losses of key genes are
among a number of genetic alterations affecting these pathways in
a number of different solid and hematological tumors [includ-
ing big killers such as breast and colon cancer, as well as rel-
atively less frequent neoplasms such as neuroendocrine tumors
(NETs), kidney cancer, and some lymphomas]. The activation
of the PI3K/Akt/mTOR pathway results in a profound distur-
bance of control of cell growth and survival, which ultimately
leads to a competitive growth advantage, metastatic competence,
angiogenesis, and therapy resistance.
Thus, this complex pathway has been taken into considera-
tion as one of the most attractive targets for the development of
anticancer agents (3, 4).
PI3K STRUCTURE AND FUNCTIONS
Phosphatidyl-inositol-3-kinases (PI3Ks) constitute a lipid kinase
family characterized by the capability to phosphorylate inositol
ring 3′-OH group in inositol phospholipids (5). Class I PI3Ks are
heterodimers composed of a catalytic (CAT) subunit (i.e., p110)
and an adaptor/regulatory subunit (i.e., p85).
This class is further divided into two subclasses: subclass IA
(PI3Kα, β, and δ), which is activated by receptors with protein
tyrosine kinase activity, and subclass IB (PI3Kγ), which is activated
by receptors coupled with G proteins (5).
Activation of growth factor receptor protein tyrosine kinases
results in autophosphorylation on tyrosine residues. PI3K is then
recruited to the membrane by directly binding to phosphotyro-
sine consensus residues of growth factor receptors or adaptors
through one of the two SH2 domains in the adaptor subunit. This
leads to allosteric activation of the CAT subunit. In a few sec-
onds, PI3K activation leads to the production of the second mes-
senger phosphatidylinositol-3,4,5-triphosphate (PI3,4,5-P3) from
the substrate phosphatidylinositol-4,4-bisphosphate (PI-4,5-P2).
PI3,4,5-P3 then recruits a subset of signaling proteins with pleck-
strin homology (PH) domains to the membrane, including protein
serine/threonine kinase-3′-phosphoinositide-dependent kinase 1
(PDK1) and Akt/protein kinase B (PKB) (5, 6). Akt/PKB, on its
own, regulates several cell processes involved in cell survival and
cell cycle progression.
As far as cell survival is concerned, Akt/PKB can inactivate pro-
apoptotic factors such as Bad and Procaspase-9, as well as the
Forkhead family of transcription factors that induce the expression
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FIGURE 1 | A schematic representation of the PI3K/Akt/mTOR pathway.
of other pro-apoptotic factors, such as Fas-ligand (FasL) (7, 8).
Akt/PKB activation has been related to an increased resistance
of prostate cancer cells to apoptosis mediated by tumor necrosis
factor (TNF)-related apoptosis inducing ligand (TRAIL)/APO-2L
(9). Finally, Akt/PKB also activates the IκB kinase (IKK), a positive
regulator of the survival factor NFκB. Notably, a strong biolog-
ical link between the NFκB and the PI3K/Akt pathways in the
modulation of anti-apoptotic effects in lymphoma cells exposed
to the irreversible inhibitor of the activation of NFκB and the
phosphorylation of IκBα BAY11-7085 has been also shown (10).
As for cell cycle progression and cell growth, several targets
of Akt are involved in protein synthesis, glycogen metabolism,
and cell cycle regulation (6), including the same mTOR, glycogen
synthase kinase-3 (GSK3), insulin receptor substrate-1 (IRS-1),
the cyclin-dependent kinase inhibitors p21CIP1/WAF1 and p27KIP1,
and possibly also Raf-1, a member of the MAPK pathway. With
regard to GSK3, Akt/PKB triggers a network that positively regu-
lates G1/S cell cycle progression through inactivation of GSK3-β,
leading to increased cyclin D1, and inhibition of the Forkhead fam-
ily transcription factors and the tumor suppressor tuberin (TSC2),
ultimately resulting in the reduction in p27Kip1 (11).
Akt STRUCTURE AND FUNCTIONS
Akt kinases belong to the AGC kinase family, related to AMP/GMP
kinases and protein kinase C. They consist of three conserved
domains, an N-terminal PH domain, a central kinase CAT
domain,and a C-terminal extension (EXT) containing a regulatory
hydrophobic motif (HM) (12). Among the Akt isoforms, the PH
domains are ~80% identical and ~30% identical to PH domains
in pleckstrin and other proteins. The linker (LINK) region con-
necting the PH domain to the CAT domain is poorly conserved
among the Akt isoforms (17–46% identical) and has no significant
homology to any other human protein (12). The consensus CAT
domain is ~90% identical among the Akt isoforms and is closely
related the PKC, PKA, SGK, and S6 subfamilies of the AGC kinase
family (12). The C-terminal EXT is ~70% identical among the Akt
isoforms and is most closely related to the PKC family (12).
mTOR STRUCTURE AND FUNCTIONS
Mammalian target of rapamycin is a key protein evolutionarily
conserved from yeast to man and is essential for life. Indeed,
embryonic mutations in mTOR proved to be lethal.
In normal cells, mTOR activity is controlled by positive and
negative upstream regulators (13). Positive regulators include
growth factors and their receptors, such as insulin-like growth
factor-1 (IGF-1) and its cognate receptor IFGR-1, members of the
human epidermal growth factor receptor (HER) family and asso-
ciated ligands, and vascular endothelial growth factor receptors
(VEGFRs) and their ligands, which transmit signals to mTOR
through the PI3K-Akt. Negative regulators of mTOR activity
include phosphatase and tensin homolog (PTEN) that inhibits
signaling through the PI3K-Akt pathway, and tuberous sclerosis
complex (TSC) 1 (hamartin) and TSC2 (tuberin). Phosphoryla-
tion of TSC2 by Akt releases its inhibitory effect on mTOR and
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up-regulates mTOR activity. Another negative regulator, LKB1, is
in an energy-sensing pathway upstream of TSC (14).
Mammalian target of rapamycin activity is carried out by two
distinct complexes: mTORC1 and mTORC2.
The mTORC1 complex is made up of mTOR, Raptor, mLST8,
and PRAS40. It is extremely sensitive to rapamycin and thus rep-
resents the target of first-generation mTOR inhibitors. It also
activates S6K and inactivates 4EBP1, leading to protein translation
and cell growth (13).
The mTORC2 complex is composed of mTOR, Rictor, Sin1,
and mLST8. It is less sensitive to rapamycin and its role in normal
cell function and oncogenesis has not been well clarified. However,
it is known to activate Akt, thereby promoting cell proliferation
and survival. The canonical pathway of mTOR activation depends
on mitogen-driven signaling through PI3K/Akt, although alter-
native non-Akt dependent activation through the Ras/MEK/ERK
pathway is now recognized (15).
Altogether, mTOR activation leads to increased synthesis of
multiple proteins. These include several that have been implicated
in the pathogenesis of multiple tumors, e.g., cyclin D1, which
allows progression of cells through the cell cycle (16), and HIF,
which drive the expression of pro-angiogenic growth factors such
as VEGF (17).
PTEN AS A REGULATOR OF THE PI3K/Akt/mTOR PATHWAY
The PTEN deleted on chromosome 10 (PTEN) is a key molecule
downstream of the PI3K/Akt pathway. This phosphatase, endowed
with dual activity on both lipids and proteins, acts as a tumor sup-
pressor by inhibiting cell growth and enhancing cellular sensitivity
to apoptosis and anoikis, i.e., an epithelial cell-peculiar type of
apoptosis triggered by alterations in integrin–extracellular matrix
interactions (18).
Phosphatase and tensin homolog is frequently mutated in sev-
eral advanced human cancers. In addition, PTEN mutations in
germ cell lines result in the rare hereditary syndrome known
as Cowden’s disease, which is associated with a higher risk
of different cancers, including breast, thyroid, and endometrial
cancers (19).
The main lipid substrate of PTEN is PI3,4,5-P3, and indeed
PTEN acts as a negative regulator of PI3K/Akt signaling. Thus,
loss of PTEN activity leads to permanent PI3K/Akt pathway
activation.
DEVELOPMENT OF mTOR INHIBITORS AS ANTICANCER
AGENTS
Rapamycin (sirolimus), an antifungal agent with immunosuppres-
sive properties, was first isolated in 1975 from the soil of the island
of Rapa Nui or Easter Island (20). Already back in the 1980s,
when tested against a panel of human cancer cell lines, rapamycin
showed a broad anticancer activity (21). However, clinical devel-
opment of rapamycin as an anticancer agent was hampered by
unfavorable pharmacokinetic properties (22).
The relatively recent development of rapamycin analogs
endowed with a more favorable pharmacokinetic profile, i.e.,
temsirolimus, everolimus, and ridaforolimus (a.k.a. deforolimus),
opened up the present era of mTOR inhibitors as anticancer
agents.
All these agents have similar structure (Figure 2) and mecha-
nism of action, but different pharmacokinetic properties. Indeed,
all these drugs are small molecule inhibitors that function intra-
cellularly, forming a complex with the FK506 binding protein-12
(FKBP-12) that is then recognized by mTOR. The resulting com-
plex prevents mTOR activity, leading to inhibition of cell cycle pro-
gression, survival, and angiogenesis. Notably, all these inhibitors
are similar to the parental compound rapamycin in that they affect
only mTORC1, and not mTORC2 (22).
TEMSIROLIMUS: PHASE III TRIALS
Temsirolimus is a pro-drug whose primary active metabolite is
rapamycin. Temsirolimus is administered intravenously on a once-
weekly schedule (23). It has been approved for the treatment of
patients with advanced renal cell carcinoma (RCC) with poor
prognostic features, and of mantle cell lymphoma (MCL) patients.
RENAL CELL CARCINOMA
Temsirolimus registration in RCC was obtained on the basis
of the positive results of a randomized, controlled, phase III
trial of temsirolimus, interferon-α, or a combination of the two
(24). In this study, 626 patients with previously untreated, poor-
prognosis, metastatic RCC were randomized to receive 25 mg
of intravenous (i.v.) temsirolimus weekly, 3 MU of interferon-
α (with an increase to 18 MU) subcutaneous (s.c.) three times
weekly, or a combination-therapy with 15 mg of temsirolimus
weekly plus 6 MU of interferon-α three times weekly. Overall sur-
vival (OS) was the primary endpoint of the trial. Patients who
received temsirolimus alone had longer OS and progression-free
survival (PFS) than patients who received interferon-α alone,
while there was no significant difference in OS between the
combination-therapy group and the interferon group. Indeed,
median OS in the temsirolimus group, the interferon-α group, and
FIGURE 2 | Structure of clinically available mTOR inhibitors.
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the combination-therapy group were 10.9, 7.3, and 8.4 months,
respectively (24).
MANTLE CELL LYMPHOMA
As far as MCL is concerned, the pivotal registration trial was
a phase III trial evaluating two dose regimens of temsirolimus
in comparison with single-agent therapy in relapsed or refrac-
tory disease (investigator’s choice) (25). Sixty-two patients with
relapsed or refractory MCL were randomly assigned to receive
one of two temsirolimus regimens: 175 mg weekly for 3 weeks fol-
lowed by either 75 mg (175/75 mg) or 25 mg (175/25 mg) weekly,
or investigator’s choice therapy from approved options. PFS was
the primary endpoint of the study. Median PFS was 4.8, 3.4, and
1.9 months for the temsirolimus 175/75, 175/25 mg, and inves-
tigator’s choice groups, respectively (25). Patients treated with
temsirolimus 175/75 mg had significantly longer PFS than those
treated with investigator’s choice therapy [p= 0.0009; hazard ratio
(HR)= 0.44]. Furthermore, objective response rate (ORR) was
significantly higher in the 175/75-mg group (22%) compared with
the investigator’s choice group (2%; p= 0.0019), while there was
no statistical difference in OS (25).
RIDAFOROLIMUS: PHASE III TRIAL
Ridaforolimus is not a pro-drug, but like temsirolimus, it was
originally administered intravenously on an intermittent schedule,
while an oral formulation has also been subsequently developed
(26, 27).
MAINTENANCE TREATMENT FOR ADULT SOFT TISSUE AND BONE
SARCOMAS
Recently, a large randomized, placebo-controlled, phase III trial
was carried out aiming to evaluate ridaforolimus activity as a main-
tenance treatment in advanced sarcomas (28). In this study, 711
patients with metastatic soft tissue or bone sarcomas who achieved
an objective response or at least a stable disease after standard
chemotherapy were randomly assigned to receive ridaforolimus
40 mg or placebo once per day, per oral administration (o.s.)
for 5 days every week. The primary endpoint was PFS. Overall,
ridaforolimus treatment led to a modest, although statistically sig-
nificant, improvement in PFS compared with placebo (17.7 vs.
14.6 weeks; HR: 0.72; 95% CI: 0.61–0.85; p= 0.001) (28).
EVEROLIMUS: PHASE III TRIALS
Everolimus is another orally available mTOR inhibitor that is usu-
ally administered on a continuous daily schedule (even though a
weekly schedule has been also tested, especially for combination
regimens) (29).
RENAL CELL CARCINOMA
Everolimus has recently been approved by the US Food and Drug
Administration (FDA) and European Medicines Agency (EMA)
for the treatment of advanced RCC after failure of treatment
with Sunitinib and/or Sorafenib, following the presentation of the
results of the RECORD-1 trial.
RECORD-1 was a phase III double-blind, randomized,
placebo-controlled trial aimed at evaluating the activity of
everolimus in patients whose disease had progressed under treat-
ment with one or two VEGFR tyrosine kinase inhibitors (TKIs)
(30). A total of 416 patients were enrolled and stratified according
to the number of previous treatments [Sorafenib or Sunitinib (1
TKI) vs. Sorafenib as well as Sunitinib (2 TKIs)] and prognos-
tic risk group. Patients were then randomized in the ratio of 2
to 1 to receive everolimus (given at the standard dose of 10 mg
daily, per o.s.) plus best supportive care (BSC), or to placebo
plus BSC. After the second interim analysis, the study was ter-
minated since the pre-specified efficacy endpoint had been met
(30). Indeed, at the final trial analysis, everolimus proved able
to significantly improve PFS when compared to placebo: 4.9 vs.
1.9 months, respectively (HR: 0.33; 95% CI: 0.25–0.43; p< 0.001)
(31). Furthermore, everolimus significantly increased median PFS
in each risk group regardless of whether patients had received one
or two prior TKIs (32), had stopped prior therapy for intolerance
(33), or of patient age (34).
NEUROENDOCRINE TUMORS
As most NETs are hypervascular (35) and synthesize and secrete
high levels of VEGF-A (36, 37), targeted (such as everolimus
and sunitinib) and untargeted (such as somatostatin analogs,
interferon-α, and thalidomide) therapies, with certain or possible
anti-angiogenic properties, have been tested in metastatic NET.
Everolimus, in association with octreotide LAR, first demon-
strated a promising antitumor activity in a phase II trial with 30
low- to intermediate-grade NET (carcinoids) patients, showing
17% of partial remission and 80% of stable disease, added to a
median PFS of 15.7 months (38).
The open-label, phase II trial RADIANT-1 enrolled 160
advanced, low- or intermediate-grade pancreatic NET (pNET)
patients, with progressive (according to RECIST criteria) dis-
ease during or after cytotoxic chemotherapy (39). One hun-
dred and fifteen patients were assigned to everolimus 10 mg/day
o.s., and 45 patients were submitted to everolimus 10 mg/day
o.s.+ octreotide LAR 30 mg/28 days intramuscular (i.m). The
response rates were 9.6% in the everolimus arm and 4.4% in the
everolimus+ octreotide LAR group. Median PFS by central radiol-
ogy review were 9.7 months for patients receiving everolimus and
16.7 months for those receiving the combination (39). Further-
more, high baseline levels of chromogranin A and neuron-specific
enolase circulating neuroendocrine markers were associated with
shorter median PFS and OS (40).
The favorable results of these previous phase II trials were then
confirmed in two international, multicenter, randomized, placebo-
controlled, phase III studies (RADIANT-2 and RADIANT-3).
In the RADIANT-2 study (41), 429 patients with advanced
progressive midgut NETs were randomized to receive everolimus
10 mg/day plus octreotide LAR 30 mg/month or octreotide LAR
plus placebo. A clinically significant improvement in PFS was
recorded in the everolimus arm compared with octreotide
LAR/placebo arm (16.4 vs. 11.3 months, respectively), even though
the pre-defined threshold for statistical significance was not
reached, according to central radiological reading (41). A sub-
sequent multivariate analysis and the local radiological read-
ing sustained the efficacy of everolimus. Furthermore, a sub-
group analysis underlined some potential primary tumor sites
in particular that could benefit, such as bronchial/lung NETs or
colonic NETs (42). Nevertheless, the precise therapeutic activity
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of everolimus in advanced progressive midgut NETs remained to
be defined (43).
In RADIANT-3 (44), the largest clinical trial conducted in
pNET patients, 410 patients with advanced pNET and progressive
disease were randomly assigned to treatment with oral everolimus
10 mg/day or placebo. Octreotide LAR was administered at the
discretion of the investigator. Everolimus was associated with an
improvement in median PFS compared with placebo (11.0 vs.
4.6 months, respectively; p< 0.0001), and with an overall tumor
response rate of 5% (44). The most common drug-related toxic-
ities were G1–2 stomatitis or aphthous ulceration (44). Further-
more, everolimus therapy correlated with a reduction in VEGF
pathway markers, such as soluble VEGF receptor 2 and placental
growth factor, suggesting an anti-angiogenic activity of everolimus
in pNET patients (45).
Even though everolimus evidently inhibited tumor growth and
delayed time-to-progression, the percentages of progression events
(i.e., appearance of new metastasis as the only cause of progres-
sion, appearance of new metastasis concurrent with progression
of preexisting metastases, lesion growth at baseline without new
metastases appearing) in the two arms (everolimus, placebo) were
similar, suggesting that everolimus delayed tumor progression
without affecting the pattern of progression in advanced pNET
patients (46).
Following the RADIANT-3, in 2011, everolimus was approved
for the treatment of progressive pNETs, but its efficacy in other
NETs remains uncertain. Given that RADIANT-2, including 51%
of small intestinal carcinoids, failed to achieve its primary end-
point, a placebo-controlled trial with everolimus as monotherapy
in progressive gastro-intestinal and lung carcinoids (RADIANT-
4) is now ongoing. In the meantime, NCCN guidelines rec-
ommend everolimus among several therapeutic options in clin-
ically significant progressive NETs, and by ENETS guidelines
in non-pNETs with progressive disease after all other medical
treatments (43).
BREAST CANCER
Recently, the combination of everolimus with the aromatase
inhibitor Exemestane has been evaluated in a randomized, phase
III trial, since a large amount of evidence supported the hypothesis
that aberrant signaling through the mTOR pathway is associated
with resistance to endocrine therapies (47).
In the BOLERO-2 phase III trial (48), 724 patients with
hormone-receptor-positive advanced breast cancer who recurred
or progressed while receiving treatment with a non-steroidal aro-
matase inhibitor in the adjuvant or metastatic setting, were ran-
domized two to one to receive everolimus and exemestane or
exemestane and placebo. PFS was the primary endpoint of the
study. A pre-planned interim analysis was performed by an inde-
pendent data and safety monitoring committee after 359 PFS
events were observed. At the time of this analysis, median PFS
assessed by the Investigators PFS was 6.9 months with everolimus
plus Exemestane and 2.8 months with Placebo plus Exemestane
(HR: 0.43; 95% CI: 0.35–0.54; p< 0.001), while centrally assessed
PFS was 10.6 and 4.1 months, respectively, again in favor of the
everolimus-containing combination (HR: 0.36; 95% CI: 0.27–0.47;
p< 0.001) (48).
OTHER INDICATIONS
Everolimus also has an established role in the treatment of two
rare conditions: renal angiomyolipomas associated with TSC or
lymphangioleiomyomatosis, as well as TSC-related subependymal
giant cell astrocytoma (SEGA), both characterized by constitutive
activation of the mTOR pathway (49).
In the EXIST-2 double-blind, placebo-controlled, phase III trial
(50), 118 patients with at least one angiomyolipoma 3 cm or larger
in its longest diameter and a definite diagnosis of TSC or spo-
radic lymphangioleiomyomatosis were randomly assigned 2:1 to
either everolimus 10 mg/day or Placebo. The primary efficacy end-
point of the study was the proportion of patients with confirmed
angiomyolipoma response of an at least 50% reduction in total
volume of target angiomyolipomas relative to baseline. Response
rate (as defined above) was 42% [33 of 79 (95% CI: 31–53%)]
for everolimus and 0% [0 of 39 (95% CI: 0–9%)] for placebo
(p< 0.0001) (50), thus suggesting the usefulness of everolimus in
this setting.
Similarly, in the EXIST-1 double-blind, placebo-controlled,
phase III trial (51), 117 patients were randomized in a 2:1 ratio
to everolimus 4.5 mg/m2/day (titrated to achieve blood trough
concentrations of 5–15 ng/mL) or Placebo. Eligible patients had a
definite diagnosis of TSC and at least one lesion with a diameter of
1 cm or greater, and either serial growth of an SEGA, a new lesion
of 1 cm or greater, or new or worsening hydrocephalus. The pri-
mary endpoint of this study was the proportion of patients with
confirmed response, i.e., a reduction in target volume of 50% or
greater relative to baseline in SEGA. Twenty-seven (35%) patients
in the everolimus group had an at least 50% reduction in SEGA
volume as compared to none in the Placebo group (95% CI: 15–52;
p< 0.0001) (51).
Taken together, these two studies suggest the possibility that
everolimus might represent a disease-modifying treatment also
for other aspects of tuberous sclerosis.
THE SAFETY PROFILE OF mTOR INHIBITORS
Adverse events observed in patients treated with mTOR inhibitors
are fairly constant, irrespective of each specific indication. They
include cutaneous and mucosal events (i.e., stomatitis and skin
rash), pulmonary dysfunction (non-infectious pneumonitis),
metabolic abnormalities (elevated blood levels of glucose, cho-
lesterol, and triglycerides), as well immune-related events (i.e.,
increased incidence of infections) (52). As far as the risk of infec-
tions is concerned, we should not forget that mTOR inhibitors
were first developed as immune suppressive agents and are still
widely used as such in the transplantation setting.
Metabolic and immune-related adverse events are clearly on-
target effects of mTOR inhibition, while cutaneous and mucosal
effects may have a less direct association with mTOR inhibition,
although inhibition of mTOR-mediated growth and tissue repair
and/or immune dysregulation have been proposed to be a factor
in mucosal epithelia with high turnover (53, 54).
In general, the incidences of key class-effect adverse events in
the three largest phase III trials of everolimus (i.e., RECORD-
1 in RCC, RADIANT-3 in pNET, and BOLERO-2 in hormone
receptor-positive, HER2-negative, advanced breast cancer) were
comparable (30, 44, 48), as summarized in Table 1.
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Table 1 | Incidence of the main adverse events (all grades and grade 3/4) reported in the three largest phase III studies of everolimus in
advanced solid tumors (RCC, pNET, and breast cancer).
RCC (27) pNET (41) Breast cancer (46)
Everolimus+BSCa Everolimus monotherapy Everolimus+exemestane
(n=274) (n=204) (n=482)
All grades (%) Grade 3/4 (%) All grades (%) Grade 3/4 (%) All grades (%) Grade 3/4 (%)
Stomatitis 44 4 64 7 59 8
Rash 29 1 49 <1 39 1
Non-infectious pneumonitis 14 4 17 2 16 3
Hyperglycemia 57 15 13 5 14 5
Infections 37 10 23 2 50 5
aBSC, best supportive care.
THE DEVELOPMENT OF PI3K AND Akt INHIBITORS AS
ANTICANCER AGENTS
In contrast to the three mTOR inhibitors discussed above, PI3K
and Akt inhibitors are still at an early development phase,and so far
no compound has reached the bedside. Despite this, three gener-
ations of compounds targeting PI3K have already been developed
over time.
PI3K AND DUAL PI3K/mTOR INHIBITORS
The first-generation of PI3K inhibitors included compounds like
Wortmannin and LY294002, which were able to bind all class I
PI3Ks, thus being called “pan-inhibitors.” These compounds have
been widely used in pre-clinical models to better characterize this
complex pathway. However, due to very poor pharmacokinetic
properties, they were never fully developed as anticancer drugs for
clinical use (55).
More recently, compounds with better pharmacokinetic prop-
erties have been developed and are currently being evaluated
within clinical trials in several malignancies (55), including gen-
itourinary cancers (56) and others. These second-generation
inhibitors are characterized by greater and isoform-specific selec-
tive activity (55).
The third generation of compounds comprises the so-called
“dual PI3K/mTOR inhibitors.” These were developed after con-
sideration that the CAT sites of PI3K and mTOR share a high
degree of sequence homology. The potential advantage of these
novel compounds (an advantage which still has to be confirmed
in vivo) is that they inhibit not only all PI3K class I isoforms, but
also mTORC1 and (more notably) mTORC2. In theory, this com-
bined activity would lead to the strongest inhibition of the whole
PI3K/Akt/mTOR pathway (57).
A list of PI3K inhibitors in pre-clinical and clinical development
is reported in Table 2.
Akt INHIBITORS
So far, compounds that target Akt ATP binding site, its PH domain,
LINK, and the protein substrate sites have been developed (12,
58). Compared to PI3K, and especially mTOR inhibitors, fewer
Akt-targeting agents have entered clinical development (58), even
though one of them, Miltefosine, has already completed a phase
III trial (59). A list of Akt inhibitors under pre-clinical and clinical
development is given in Table 3.
MECHANISMS OF RESISTANCE TO PI3K/Akt/mTOR
INHIBITORS
Despite all the successes (achieved with mTOR inhibitors) and
expectations (related to novel anti-PI3K and Akt drugs), none of
the above drugs is currently able to cure a single patient with
cancer.
As with all antineoplastic agents, this is mainly due to the devel-
opment of resistance. The underlying molecular basis of resistance,
either intrinsic or acquired, remains largely unknown and has
not been well characterized. So far, multiple mechanisms of resis-
tance to targeted agents have been proposed, including secondary
target mutations, activation of alternative, parallel, signaling path-
ways, and amplification of downstream alterations within the same
pathway (60).
Resistance to mTOR inhibitors has been at least partially clar-
ified. Indeed, it is often linked to different negative feedback
loops. In one loop, mTORC1 inhibition leads to upregulation of
receptor tyrosine kinases (RTKs or substrates) such as platelet-
derived growth factor receptors (PDGFRs) and insulin receptor
substrate-1 (IRS-1), resulting in increased PI3K-dependent Akt
phosphorylation at Ser473. In another loop, mTORC1 inhibition
leads to PI3K-Ras activation, which leads to an increase in MAPK
signaling (61–63).
Furthermore, aberrant activation of MYC may contribute to
acquired resistance to PI3K/Akt/mTOR-targeted therapy. Indeed,
targeting this pathway may cause MYC activation through PDK1-
dependent MYC phosphorylation and MYC amplification, which
is parallel to PIK3CA-dependent Akt and MAPK activation, thus
attenuating the therapeutic effect of PI3K/Akt/mTOR inhibitors
(64–66).
Finally, a recent report analyzed SGK (serum- and
glucocorticoid-regulated kinase) levels and the relative sensitivity
of a panel of breast cancer cells toward two distinct Akt inhibitors
(67). This study showed a number of Akt-inhibitor-resistant lines
displaying markedly elevated SGK1 that also exhibited significant
phosphorylation of the SGK1 substrate NDRG1 [neuroblastoma-
derived Myc (N-Myc) downstream-regulated gene 1]. In contrast,
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Table 2 | Phosphatidylinositol-3-kinase and “dual PI3K and mTOR” inhibitors in development [modified from ref. (53)].
Group Selectivity Compound/company/route
of administration
Main feature(s) Ongoing trials in
Pan-class I Class I PI3K GDC-0941 (Roche/Genentech)
oral
Proved able to synergize with different
agents (e.g., rapamycin, docetaxel,
HER-targeting agents)
Breast, NHL, NSCLC
BKM120 (Novartis) oral Peculiar ability to penetrate the blood-brain
barrier
Breast, colo-rectal, endometrial,
GIST, leukemia, melanoma,
NSCLC, pancreatic, RCC,
transitional cell carcinoma,
squamous cell carcinoma of the
head and neck
PX866 (Oncothyreon) oral Proved able to synergize with chemotherapy,
radiation, and targeted agents (e.g., EGFR
inhibitors)
Colo-rectal, glioblastoma,
NSCLC, squamous cell
carcinoma of the head and neck
Isoform-specific PI3Kα GDC-0032 (Roche/Genentech)
oral
Sparing the β-isoform of PI3K, it may reduce
some undesired adverse events, e.g.,
metabolic abnormalities
Different solid cancers
PI3Kβ GSK2636771 (GSK) oral Studied especially in patients whose tumors
lack PTEN expression
Different solid cancers
PI3K-γ
and -δ
IPI-145 (Infinity) oral Since PI3K-γ and -δ isoforms are
preferentially expressed in leukocytes,
where they have distinct and non-overlapping
roles in key cellular functions (e.g., cell
proliferation, differentiation, migration, and
immunity) it may be particularly active in
hematological malignancies (as well as in
inflammatory diseases)
Different hematological
malignancies
PI3Kδ CAL-101 (Gilead sciences) oral Since PI3K-δ is preferentially expressed in
leukocytes, may be particularly active in
hematological malignancies; furthermore,
the targeted inhibition of PI3K-δ is designed
to preserve PI3K signaling in normal cells
AML, CLL, HL, NHL, multiple
myeloma
Dual PI3K/mTOR PI3K and
mTOR
NVP-BEZ235 (Novartis) oral This drug also potently inhibits ATM and
DNA-PKcs, the two major kinases
responding to ionizing radiation-induced DNA
double-strand breaks, resulting in significant
attenuation of double-strand breaks repair.
May thus be developed as a radiosensitizer.
Also the first PI3K inhibitor to enter clinical
trials, in 2006; issues in its bioavailability are
presently hampering its development
Breast, RCC
NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; GIST, gastro-intestinal stromal tumor; RCC, renal cell carcinoma; AML, acute myeloid leukemia;
CLL, chronic lymphocytic leukemia; HL, Hodgkin’s lymphoma.
most Akt-inhibitor-sensitive cell lines displayed low or unde-
tectable levels of SGK1. Intriguingly, despite low SGK1 levels,
several Akt-inhibitor-sensitive cell lines showed marked NDRG1
phosphorylation that, unlike resistant cells, were suppressed by
Akt inhibitors. Furthermore, SGK1 knockdown markedly reduced
proliferation of Akt-inhibitor-resistant cells, but not Akt-sensitive
cells (67). Taken together, these results clearly suggest that SGK1
levels, as well as responses of NDRG1 phosphorylation to Akt
inhibitor administration, could help us predict the sensitivity or
resistance of tumor cells to Akt-targeting drugs.
Autophagy may represent another mechanism of resistance
from Akt/mTOR targeting. Indeed, autophagy induction proved
able to protect MCL cells from Akt/mTOR inhibition. Fur-
thermore, selective triple knockdown of the autophagy genes
ATG7, ATG5 and ATG3, and pre-treatment with the autophagy
inhibitor hydroxychloroquine, efficiently overcame the resistance
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Table 3 | Akt inhibitors in development.
Compound/drug
(company)
Characteristics Clinical development
Miltefosine
(Zentaris GmbH)
• As 6% topical solution, proved able to increase time to treatment failure
(in a double-blind, placebo-controlled, phase III trial) in cutaneous
metastases from breast cancer patients
• Registered and used in India, Colombia, and Germany for the treatment
of visceral and cutaneous leishmaniasis
• Targets HIV-infected macrophages. The HIV protein Tat activates
pro-survival PI3K/Akt pathway in primary human macrophages.
Miltefosine acts by inhibiting the PI3K/Akt pathway, thus removing the
infected macrophages from circulation, without affecting healthy cells
Perifosine
(Keryx/Aeterna Zentaris)
• Orally active alkyl-phosphocholine compound
• Modulates membrane permeability, membrane lipid composition,
phospholipid metabolism, and mitogenic signal transduction, resulting in
cell differentiation and inhibition of cell growth
• Inhibits the anti-apoptotic mitogen-activated protein kinase (MAPK)
pathway and modulates the balance between the MAPK and
pro-apoptotic stress-activated protein kinase (SAPK/JNK) pathways,
thereby inducing apoptosis
Stopped after several phase II studies
MK2206
(Merck/Astra Zeneca)
• Orally bioavailable allosteric inhibitor of the serine/threonine protein
kinase Akt (protein kinase B)
• Binds to and inhibits the activity of Akt in a non-ATP competitive manner,
which may result in the inhibition of the PI3K/Akt signaling pathway and
tumor cell proliferation and the induction of tumor cell apoptosis
Phase I and II trials ongoing as single-agent
or in combination with other drugs – e.g.,
chemotherapeutic, hormonal, and other
targeted agents
RX-0201
(Rexahn pharmaceuticals)
• A 20-mer antisense oligodeoxynucleotide directed against Akt
• Binds to Akt-1 mRNA, inhibiting translation of the transcript; suppression
of Akt-1 expression may result in the inhibition of cellular proliferation,
and the induction of apoptosis in tumor cells that overexpress Akt-1
Phase II study in combination with
gemcitabine in pancreatic cancer closed
Erucylphosphocholine
(a.k.a. ErPC or AEZS-127)
Aeterna Zentaris
• Structurally related to Perifosine, it inhibits Akt, but also impacts other
signaling pathways (most prominently, Raf-MEK-ERK)
• Intravenous use
Currently under pre-clinical development
PBI-05204
(a.k.a. Oleandrin)
(Phoenix biotechnology)
• A lipid soluble cardiac glycoside derived from Nerium oleander
• Specifically binds to and inhibits the α3 subunit of the Na/K-ATPase pump
in human cancer cells. This may inhibit the phosphorylation of Akt,
upregulate MAPK, inhibit NF-κb activation, and inhibit FGF-2 export and
may downregulate mTOR thereby inhibiting p70S6K and S6 protein
expression, ultimately resulting in the induction of apoptosis
• As cancer cells with relatively higher expression of the α3 subunit and
with limited expression of the α1 subunit are more sensitive to oleandrin,
one may predict the tumor response to oleandrin based on the tumors
Na/K-ATPase pump protein subunit expression
Early clinical development
GSK690693 (GSK) • An aminofurazan-derived inhibitor of Akt kinases 1, 2, and 3
• May also inhibit other protein kinases including protein kinase C (PKC)
and protein kinase A (PKA)
Early clinical development
XL-418 (Exelixis) • A dual inhibitor of Akt and p70S6K • Enhance apoptosis in combination with
XL647, an inhibitor of multiple receptor
tyrosine kinases including EGFR, HER2,
and VEGFR, in pre-clinical tumor models
• In a phase I study, low drug exposure was
achieved and the trial was thus stopped
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to Akt/mTOR inhibitors in this model, leading to the activa-
tion of the mitochondrial apoptotic pathway (68, 69). Taken
together, these results suggest that counteracting autophagy may
represent an attractive strategy for sensitizing lymphoma cells to
everolimus-based therapy. Furthermore,autophagy facilitates can-
cer cell resistance also to cytotoxic chemotherapy and radiation
treatment (70).
CONCLUSION
The PI3K/Akt/mTOR pathway represents a good example of the
concept of redundancy in biological systems, particularly in can-
cer cells. Indeed, cancer responds to chronic treatment with drugs
targeting a single pathway by adapting its signaling circuitry, tak-
ing advantage of pathway redundancy and routes of feedback
and crosstalk to maintain their function and thus escape from
drug-induced growth inhibition and death (71–73).
That is why, despite recent successes (achieved in completely
different diseases such as kidney and breast cancer, pNETs, and
other malignancies), tumors ultimately evade inhibition of this
pathway.
Novel agents targeting PI3K/Akt/mTOR promise further
improvement of the results achieved so far through higher selectiv-
ity and potency, as well as to combinability with other therapeutic
strategies. However, only translational research, addressing this
variegated and complex network of highly integrated signaling
pathways and mechanisms of resistance to their inhibition, will be
able to help us take another step forward.
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